Paper

A phase 3 study of revumenib plus venetoclax/azacitidine in adults with newly diagnosed NPM1 -mutated or KMT2A -rearranged acute myeloid leukemia ineligible for intensive chemotherapy (EVOLVE-2/HO177/AMLSG35-24/ACT-HOV-AML-002).

Journal of Clinical Oncology · 2026 · G A Huls, Michael W.M. Kühn, Paresh Vyas et al.